Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings.

Cecchi M, Moore DK, Sadowsky CH, Solomon PR, Doraiswamy PM, Smith CD, Jicha GA, Budson AE, Arnold SE, Fadem KC.

Alzheimers Dement (Amst). 2015 Oct 2;1(4):387-94. doi: 10.1016/j.dadm.2015.08.004. eCollection 2015 Dec.

2.

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD.

Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):192-9. doi: 10.1097/WAD.0000000000000093.

PMID:
25973909
3.

Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.

Farlow MR, Sadowsky CH, Velting DM, Meng X, Islam MZ.

CNS Neurosci Ther. 2015 Jun;21(6):513-9. doi: 10.1111/cns.12385. Epub 2015 Feb 10.

PMID:
25675992
4.

Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

Sadowsky CH, Micca JL, Grossberg GT, Velting DM.

Prim Care Companion CNS Disord. 2014 Sep 4;16(5). doi: 10.4088/PCC.14r01654. eCollection 2014. Review.

5.

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S.

JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144.

PMID:
25622185
6.

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

PMID:
25437301
7.

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.

Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group; AV45-A11 Study Group.

Mol Psychiatry. 2014 Sep;19(9):1044-51. doi: 10.1038/mp.2014.9. Epub 2014 Mar 11.

8.

Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.

Kerbage C, Sadowsky CH, Tariot PN, Agronin M, Alva G, Turner FD, Nilan D, Cameron A, Cagle GD, Hartung PD.

Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):738-45. doi: 10.1177/1533317513520214. Epub 2014 Feb 13.

PMID:
24526759
9.

Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.

Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, Doraiswamy PM, Lu M, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Zehntner SP, Carpenter AP, Joshi AD, Mintun MA, Pontecorvo MJ, Skovronsky DM, Sue LI, Beach TG.

J Neuropathol Exp Neurol. 2014 Jan;73(1):72-80. doi: 10.1097/NEN.0000000000000028.

10.

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.

Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA.

Alzheimers Res Ther. 2013 Nov 26;5(6):59. doi: 10.1186/alzrt224. eCollection 2013.

11.

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M.

CNS Neurosci Ther. 2013 Oct;19(10):745-52. doi: 10.1111/cns.12158. Epub 2013 Aug 7.

12.

Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study.

Kerbage C, Sadowsky CH, Jennings D, Cagle GD, Hartung PD.

Front Neurol. 2013 May 27;4:62. doi: 10.3389/fneur.2013.00062. eCollection 2013.

13.

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.

Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali Doraiswamy P, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ, Skovronsky DM; AV45-A11 study group.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.

14.

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.

Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; 45-A17 Study Group.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a.

PMID:
23203162
15.

Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A05 Study Group.

Neurobiol Aging. 2013 Mar;34(3):822-31. doi: 10.1016/j.neurobiolaging.2012.06.014. Epub 2012 Aug 9.

16.

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.

Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ; AV45-A11 Study Group.

Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11.

17.

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM; AV-45-A16 Study Group.

Lancet Neurol. 2012 Aug;11(8):669-78. Epub 2012 Jun 28. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22749065
18.

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.

Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE, Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM.

Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.

PMID:
22633529
19.

Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.

Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.

Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x. Epub 2012 May 18.

PMID:
22607530
20.

Practical guidelines for the recognition and diagnosis of dementia.

Galvin JE, Sadowsky CH; NINCDS-ADRDA.

J Am Board Fam Med. 2012 May-Jun;25(3):367-82. doi: 10.3122/jabfm.2012.03.100181. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk